4D pharma plc - DDDD

4D pharma plc engages in the research, development, and production of live biotherapeutic products. The company’s development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn’s disease, as well as Rosburix for Paediatric Ulcerative Colitis. It also develops immuno-oncology products, including MRx0518 for solid tumors; respiratory products, such as MRx0004 for asthma and MRx0001 for allergic asthma; autoimmune products comprising MRx0002 for multiple sclerosis and MRx0006 for rheumatoid arthritis; and CNS products for autism. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of KEYTRUDAÂ and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.